Table 2.
Clinical and genotypic characteristics of 92 T-ALL patients
| Clinical trial microarray platform | COG 9404*: U133 Plus 2.0 | COG 8704†: U133A |
|---|---|---|
| Clinical characteristics and demographics | ||
| Sample size, no. | 50 | 42 |
| Male/female, no. | 39/11 | 36/6 |
| Median age, y (range) | 9.4 (2.0-18.2) | 9.2 (1.8-19.2) |
| Median initial WBC ×109/L (range) | 187.5 (9.7-874.8) | 97 (2.3-751.8) |
| NCI standard risk (CNS 2 or 3) | 2 (1) | 7 (3) |
| NCI high risk (CNS 2 or 3) | 48 (20) | 35 (15) |
| Ethnic status, no. | ||
| White, non-Hispanic | 37 | 34 |
| Black, non-Hispanic | 9 | 5 |
| Hispanic | 3 | 3 |
| Other | 1 | — |
| Patient outcome, no. | ||
| Induction failure | 6 | 1 |
| Postremission relapse within 4 y | 14 | 16 |
| CCR for greater than 4 y | 30 | 25 |
| Cytogenetic characteristics, no. | ||
| Normal | 5 | 21 |
| Unknown | 36 | 6 |
| t(11;14) | — | 2 |
| t(8;14) | — | 2 |
| t(5;17) | — | 1 |
| t(1;7) | — | 1 |
| del(6q) | 2 | 4 |
| del(5q) | 1 | 1 |
| Other aberrations | 6 | 4 |
— indicates not done.
*
Other aberrations (9404): 45,46,XX,add(7)(p15),t(12;22)(q13;q13); 46,XY,del(10)(q?22q?24)[11]/46,XY[9]; 47,XY,+7 46,XX,t(10p;11q)/45,XX,t(10p;11q),der(12)t(12p;17q), −17; 46,XX,t(4;8)(p14;q24.1) 49,XY,+6,+16,+18.
†
Other aberrations (8704): 45,XX,−9,−11,inv(1)(p13;q42), +der(9)t(9;?)(p13;?), +der(11)t(11;?)(q23;?); 46,XY,inv(8)(p23;q22); 46,Y,−X,+der(x)ins(x;?), −16,dup(2),del(10),+der(16)t(1;16)z; 45,X,−Y.